MSD Animal Health announces new vaccine against streptococcis

MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, has announced the introduction of a new vaccine AQUAVAC® Strep Sa-Si, to protect against streptococcosis in fish in Latin America.

Indicated for the active immunisation of tilapia (Oreochromis sp.) and other susceptible fish species to reduce mortality and disease due to streptococcosis caused by Streptococcus agalactiae (serotype Ib) and Streptococcus iniae, AQUAVAC® Strep Sa-Si Strep Sa-Si has a demonstrated onset of immunity from one week after vaccination, with a demonstrated duration of immunity for at least 12 weeks in laboratory trials and throughout the production cycle in field trials[i].
 

Image credit: NIAID on Flickr
(CC BY 2.0)

'MSD Animal Health is pleased to announce the approval of a new vaccine that provides protection to tilapia against streptococcosis, the most significant health challenge of tilapia.  AQUAVAC® Strep Sa-Si will benefit tilapia health and tilapia producers throughout Latin America[ii],' said Kasha Cox, Global Lead Aquaculture, MSD Animal Health. 'Tilapia grown in Latin America helps the region meet the growing demand for a safe and affordable protein source that helps contribute to a nutritious diet. MSD Animal Health continues to demonstrate its commitment to supporting the tilapia producers and the health and welfare of the fish they are raising.'

Read the full article on the International Aquafeed website, HERE.

The Aquaculturists

---